Kaylynn is an Associate in our antitrust, competition, and trade practice based in Washington, D.C. She assists clients with antitrust matters and merger review.
Prior to joining Freshfields, Kaylynn worked at two other global law firms where she advised clients on a variety of antitrust issues, including several in-depth Second Request investigations by the DOJ and FTC, merger control considerations and risk assessments for various transactions, and counseling on certain contractual arrangements and partnerships between competitors and other industry participants.
During law school, Kaylynn interned at the Department of Justice Antitrust Division, the Securities and Exchange Commission, and the Federal Trade Commission.
- Maze Therapeutics on proposed acquisition of an excusive license by Sanofi, including an in-depth investigation by the US FTC*
- Figma on various competition matters, including the proposed $20bn acquisition by Adobe resulting in an in-depth investigation by the US DOJ and parallel investigations by the CMA and EC*
- Shockwave Medical on its $13bn acquisition by Johnson & Johnson*
- Databricks on competition aspects of its $1bn acquisition of Tabular*
- RHI Magnesita on its acquisition of Resco Products, including an in-depth investigation by the US DOJ*
- AstraZeneca on its $39bn acquisition of Alexion including securing unconditional clearance in more than 20 antitrust and foreign direct investment jurisdictions
- Cisco Systems on competition aspects for various transactions, including securing unconditional antitrust approvals in the US, Germany, Austria, and the UK for its acquisition of Isovalent*
- Embracer on the acquisition of Gearbox by Take-Two, including securing unconditional antitrust clearances in the US and Turkey*
- Cargotec Corp. on its proposed merger with Konecranes, including an in-depth investigation by the US DOJ
*Work from a previous firm
